Grifols, S.A. (NASDAQ:GRFS) Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA cut its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 3.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,626,603 shares of the biotechnology company’s stock after selling 88,382 shares during the period. Pictet Asset Management Holding SA owned 0.38% of Grifols worth $19,542,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. R Squared Ltd purchased a new stake in Grifols during the fourth quarter valued at about $28,000. GAMMA Investing LLC lifted its position in Grifols by 44.5% during the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 1,527 shares in the last quarter. Blue Trust Inc. grew its stake in Grifols by 254.0% during the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock worth $52,000 after buying an additional 4,970 shares during the period. Envestnet Portfolio Solutions Inc. acquired a new stake in shares of Grifols in the fourth quarter worth $77,000. Finally, Raymond James Financial Inc. purchased a new position in shares of Grifols in the 4th quarter valued at $91,000.

Grifols Stock Performance

Grifols stock opened at $7.11 on Tuesday. The firm has a market capitalization of $4.89 billion, a PE ratio of 6.08 and a beta of 0.35. Grifols, S.A. has a one year low of $5.79 and a one year high of $9.96. The stock’s 50 day moving average price is $7.56 and its 200 day moving average price is $8.03. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley started coverage on Grifols in a report on Wednesday, February 12th. They issued an “overweight” rating for the company.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.